



UPDATE • JULY 2015

## NEWBORN CLINICAL TRIAL OF EDI200

As you read in the Spring *edlines* newsletter the XLHED Newborn Clinical Trial of EDI200 has enrolled 10 newborns to date! The clinical study team and the team at Edimer are now focused on collecting and analyzing all the data from the babies who have participated in the study up until this point. The data includes assessments and measurements such as: blood laboratory tests, looking at sweat ducts and sweat production, measuring how the babies are able to regulate their temperature, and, as they get older, looking at dentition. Looking at the data as a whole will provide the information necessary to determine what the appropriate next steps are.

*We remain grateful to the families who have participated in the trial, as well as those who have considered participating. This clinical trial represents a significant milestone for the ectodermal dysplasias community and we are excited to be a part of it.*

For more information about the XLHED Newborn Clinical Trial of EDI200 please visit:

[www.XLHEDnetwork.com](http://www.XLHEDnetwork.com).

**If you have any questions, please do not hesitate to contact us – we are here to help!**

Tessa Field, MS, Genetic Counselor  
Manager, Clinical Outreach  
[tessa@edimerpharma.com](mailto:tessa@edimerpharma.com)

Ramsey Johnson, MSM  
Senior Director, Clinical Operations & Regulatory  
[ramsey@edimerpharma.com](mailto:ramsey@edimerpharma.com)